Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

Abstract: Combined therapy for a solid tumor, comprising an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g, G9.2-17), and one or more chemotherapeutics, for example, gemcitabine, paclitaxel, or a combination thereof.

Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

Abstract: The invention provides compositions and methods for binding Ras in a nucleotide free state (apo RAS) and inhibiting Ras signaling. In one embodiment, the invention provides monobodies that specifically bind apo RAS and methods of use. Thus, in diseases and conditions where a reduction of Ras signaling is beneficial, such inhibitory compositions act as therapeutics.

Abstract: Aspects of the disclosure relate to compositions of enzyme-binding polypeptides (EBPs) that modify the substrate specificity of an enzyme and a method for identifying an EBP that modifies substrate specificity of an enzyme binding at least one substrate, the method comprising: contacting the enzyme with a polypeptide library comprising a plurality of EBPs that bind different epitopes of the enzyme; identifying EBPs that bind to the enzyme to form an EBP-enzyme complex; assaying for the activity level and substrate specificity of the EBP-enzyme complex; and identifying EBPs that modify the substrate specificity of the enzyme by identifying EBPs that, when in an EBP-enzyme complex, have a different substrate specificity than un-complexed EBP; wherein the catalytic rate constant of the EBP-enzyme complex is ?50% of the un-complexed enzyme for at least one substrate and/or wherein the EBP-enzyme complex retains binding to a substrate.

Abstract: A liquid jetting apparatus includes a nozzle plate having a nozzle, and a channel unit having a first surface facing and joined with the nozzle plate. The channel unit has a first channel member having the first surface, and a second channel member having a second surface facing and joined with the first channel member. The second channel member is formed with a first pressure chamber, a second pressure chamber, a first opening and a second opening defined by the second surface, a first connecting channel connecting the first pressure chamber and the first opening, and a second connecting channel connecting the second pressure chamber and the second opening. The first channel member is formed with a third connecting channel connecting the first pressure chamber and the second pressure chamber.

Abstract: There is provided liquid discharge head including: channel substrate which has first surface; and actuator substrate having second surface. A trap chamber configured such that the adhesive is trapped in the trap chamber in a case that the first and second surfaces are adhered to each other, an inflow channel configured such that the adhesive flows into the inflow channel, and an atmosphere communicating channel are formed in the channel substrate. The trap chamber has first and second ends in first direction and first and second ends in second direction. End of the inflow channel is located at the first end in the first direction and the second end in the second direction of the trap chamber. End of the atmosphere communicating channel is located at the second end in the first direction and the first end in the second direction of the trap chamber.

Abstract: The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.

Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

Abstract: There is provided a liquid discharge head including a channel unit including: individual channels aligned in a first direction, and first and second common channels extending in the first direction. Each of the individual channels includes: a nozzle, a pressure chamber, and first and second communicating channels. The channel unit further includes a linking channel linking two pieces of the second communicating channel to each other. Resistance, in one of the two individual channels, from one end of the second communicating channel up to a linking part of the second communicating channel at which the second communicating channel is linked to the linking channel is different from resistance, in the other of the two individual channels, from the one end of the second communicating channel up to the linking part of the second communicating channel.

Abstract: A liquid discharge apparatus is provided, including a liquid discharge head including: an upper substrate, a plurality of piezoelectric elements, an intermediate substrate, a lower substrate and a plurality of individual traces arranged on the upper substrate and extending toward the contacts arranged on the one end side in the second direction from the plurality of piezoelectric elements respectively.

Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.

Abstract: Disclosed herein are methods for treating solid tumors (e.g., pancreatic adenocarcinoma (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC)), or Cholangiocarcinoma and others), including, but not limited to, metastatic tumors, using an anti-Galectin-9 antibody.

Abstract: Disclosed herein are methods for identifying a subject as having certain solid cancers such as breast cancer, colorectal colon cancer, or non-small cell lung cancer, or being at risk for the cancer based on the level of Galectin-9 in a biological sample (e.g., a blood sample) from a subject suspected of having the solid cancer.

Abstract: Provided are proteins or peptides, which may be referred to as monobodies. Fusion proteins and proteolysis targeting chimeras (PROTACs) comprising the proteins or peptides are also provided. Also provided are compositions of the proteins or peptides of the present disclosure, as well as compositions of fusion proteins and compositions of PROTACs. Methods of treating an individual in need of treatment are also provided. The methods may be to treat an individual suffering from or suspected of having KRAS(G12V), KRAS(G12S), KRAS(G12A) and/or KRAS(G12C)-associated cancers. A method may be for inhibiting ERK activation and/or proliferation of KRAS(G12V), KRAS(G12S), KRAS(G12A) and/or KRAS(G12C)-associated cancers.

Abstract: There is provided a liquid discharge head including a channel member and a temperature sensor. The channel member includes: a plurality of individual channels aligned in a first direction; a first common channel extending in the first direction and communicating with the plurality of individual channels; a second common channel extending in the first direction, communicating with the plurality of individual channels and arranged side by side to the first common channel in a second direction crossing the first direction; and a connecting channel extending in the second direction and connecting an end in the first direction of the first common channel and an end in the first direction of the second common channel. The temperature sensor overlaps with the connecting channel in the second direction.

Abstract: There is provided a liquid discharge apparatus configured to discharge a liquid, including a channel member for the liquid. The channel member is formed to include: individual channels; a first and second manifold channels; and a bypass channel. Each of the individual channels and the bypass channel are all connected to the first manifold channel on only one of an upper and lower sides of a central portion between upper and lower surfaces of the first manifold channel, and connected to the second manifold channel on only one of upper and lower sides of a central portion between upper and lower surfaces of the second manifold channel. A channel resistance of the bypass channel is smaller than that of the individual channels.

Abstract: A liquid discharge head includes: a supply manifold; a feedback manifold; and a plurality of individual flow channels. Each of the individual flow channels includes: a supply portion, a descender portion, and a feedback portion. The supply manifold has a plurality of supply ports, and the feedback manifold has a plurality of feedback ports. A distance between the center of the supply manifold in one direction and the plurality of supply ports of the supply manifold is longer than ¼ of a width of the supply manifold in the one direction, and a distance in the one direction between the center of the feedback manifold in the one direction and the plurality of feedback ports of the feedback manifold is shorter than ¼ of a width of the feedback manifold in the one direction.

Abstract: A liquid discharge apparatus is provided, including a liquid discharge head including: an upper substrate, a plurality of piezoelectric elements, an intermediate substrate, a lower substrate and a plurality of individual traces arranged on the upper substrate and extending toward the contacts arranged on the one end side in the second direction from the plurality of piezoelectric elements respectively.

Abstract: A liquid ejection head includes pressure chambers arrayed in an array direction, a supply manifold extending in the array direction, a return manifold disposed below the supply manifold, and a bypass channel. Each pressure chamber receives a pressure for ejecting liquid from a corresponding nozzle. The supply manifold communicates with the pressure chambers and includes a supply opening through which liquid enters from an exterior. The return manifold is formed by a first forming unit to extend in the array direction and communicate with the pressure chambers, and includes a return opening through which liquid exits to the exterior. The bypass channel connects the supply manifold and the return manifold. The first forming unit includes a first top surface defining a top surface of the return manifold, and a first protrusion protruding downward from the first top surface and having a lower end at which the bypass channel is open.